Healthy Volunteer
Conditions
Keywords
tapentadol, NUCYNTA, CG5503, R331333, pharmacokinetics, healthy volunteer
Brief summary
The purpose of this study is to evaluate the dose-proportionality of the pharmacokinetics of tapentadol (CG5503) in healthy Japanese and Korean adult male participants.
Detailed description
This is a single-dose, open-label, single-center, randomized, four-way crossover study, ie, participants and investigator know the identity of the drug, which is assigned by chance, like flipping a coin, and participants may receive different interventions sequentially during the study. The study will consist of 4 treatment periods. A single dose of tapentadol (CG5503) will be administered orally with 240 mL of water under fasted conditions. All participants will receive 1 of the following 4 oral treatments in each period. Treatment A: One 25-mg tablet (25 mg) of tapentadol (CG5503) Treatment B: One 50-mg tablet (50 mg) of tapentadol (CG5503) Treatment C: One 100-mg tablet (100 mg) of tapentadol (CG5503) Treatment D: Two 100-mg tablets (200 mg) of tapentadol (CG5503) Each period will be separated by 7 - 14 days.
Interventions
DRUGtapentadol (CG5503) ER two 100-mg TRF
200mg TRF single oral dose
50mg TRF single oral dose
25mg TRF single oral dose
100mg TRF single oral dose
Sponsors
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
20 Years to 45 Years
Healthy volunteers
Yes
Inclusion criteria
* Healthy Japanese and Korean male volunteers, inclusive * Body mass index (BMI) between 18.5 and 25 kg/m², inclusive, and a body weight of not less than 50 kg * Japanese volunteers must have resided outside of Japan for no more than 5 years, and their parents and maternal and paternal grandparents are Japanese. * Korean volunteers must have resided outside of Korea for no more than 5 years and their parents and maternal and paternal grandparents are Korean.
Exclusion criteria
* History of or current clinically significant medical illness including (but not limited to) cardiac arrhythmias or other cardiac disease * History of hematologic disease, coagulation disorders (including any abnormal bleeding or blood dyscrasias), lipid abnormalities * History of significant pulmonary disease, including bronchospastic respiratory disease * History of diabetes mellitus, renal or hepatic insufficiency, thyroid disease, neurologic or psychiatric disease, infection, or any other illness that the investigator considers should exclude the participant or that could interfere with the interpretation of the study results * Use of any prescription or nonprescription medication (including vitamins and herbal supplements), except for paracetamol-acetaminophen, within 14 days before the first dose of the study drug is scheduled * History of, or a reason to believe a participant has a history of drug or alcohol abuse within the past 5 years
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pharmacokinetic profile, as measured by Cmax, AUC, tmax, kel, t1/2 | Two days |
Secondary
| Measure | Time frame |
|---|---|
| Number of participants with adverse events | Time of screening to end of treatment (up to 9.5 weeks) |
Outcome results
None listed